ALK-IN-26
CAS No. 2447607-85-2
ALK-IN-26( —— )
Catalog No. M37104 CAS No. 2447607-85-2
ALK-IN-26 is an ALK inhibitor with potential anticancer activity, demonstrating antiproliferative effects against glioblastoma and inducing apoptosis, autophagy, and necrosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 53 | Get Quote |
|
| 5MG | 75 | Get Quote |
|
| 10MG | 117 | Get Quote |
|
| 25MG | 220 | Get Quote |
|
| 50MG | 348 | Get Quote |
|
| 100MG | 503 | Get Quote |
|
| 500MG | 1071 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameALK-IN-26
-
NoteResearch use only, not for human use.
-
Brief DescriptionALK-IN-26 is an ALK inhibitor with potential anticancer activity, demonstrating antiproliferative effects against glioblastoma and inducing apoptosis, autophagy, and necrosis.
-
DescriptionALK-IN-26 is an ALK inhibitor with IC50 value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26 has good pharmacokinetic properties and blood-brain barrier (BBB) permeability. ALK-IN-26 can induce apoptosis, autophagy and necrosis. ALK-IN-26 can be used in glioblastoma studies.
-
In VitroApoptosis AnalysisCell Line:GL261 Concentration:0.5 μM, 1.0 μM, 2.0 μM Incubation Time:24 h, 48 h, 72 h Result:Induced apoptosis of glioblastoma in a concentration- and time-dependent manner, and caused the cells (24.5%) entered the S phase but barely proceeded to the G2/M phase when treated with 1 μM for 72 h.Cell Viability AssayCell Line:GL216, U87MG, HelaConcentration:0.5 μM, 1.0 μM, 2.0 μM, 5 μM, 10 μM for GL216 and U87MG cells 5 μM, 10 μM, 20 μM, 40 μM, 80 μM, 160 μM for Hela cells Incubation Time:24 h, 48h, 72h Result:Inhibited the activity of GL216 cells with the inhibition rate of cells at 80% when incubated with 2 μM for 72 h and inhibited U87MG cells viability with a dose- and time-dependent manner, while showed limited inhibition on Hela cells, even at 160 μM, the inhibition rate is less than 50%. Can inhibit the activity of ALK tyrosine kinase with a dose-dependent manner.Cell Autophagy Assay Cell Line:GL261 Concentration:0.5 μM, 1.0 μM, 2.0 μM Incubation Time:24 h Result: Induced autophagy death in glioblastoma cells.
-
In VivoAnimal Model:Male C57BL/6J miceDosage:5 mg/kgAdministration:Intravenous injection (i.v.), Single dose Result:Could be rapidly absorbed (Tmax = 0.58 h) with an acceptable half-life (T1/2 = 3.55 h) and bioavailability (F = 38.4%).Animal Model:Male C57BL/6J mice Dosage:20mg/kg Administration:Intraperitoneal injection (i.p.), Single doseResult:Could enter the body at concentrations up to 2.7μmol/kg (after 2 h administration at 20 mg/kg) andpenetrate the blood-brain barrier.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2447607-85-2
-
Formula Weight405.51
-
Molecular FormulaC24H23NO3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S(=O)(C1=CC=C(C=C1)C)N2C=C(C=3C=CC=CC32)CC=4C=C(C(O)=C(C4)C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Feng L, et al. Synthesis and Bioevaluation of 3-(Arylmethylene) indole Derivatives: Discovery of a Novel ALK Modulator with Antiglioblastoma Activities[J]. Journal of Medicinal Chemistry, 2023.?
molnova catalog
related products
-
INCB-000928
Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.
-
CH5424802 analog
CH5424802 analog is a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
-
CEP-28122 mesylate
A highly potent and selective, orally active ALK inhibitor with IC50 of 1.9 nM.
Cart
sales@molnova.com